*Johnson & Johnson: 3Q Innovative Medicine Operational Sales Growth Driven Primarily by Tremfya, Darzalex, Carvykti, Tecvayli, Rybrevant/Lazcluze, Erleada, Caplyta and Spravato >JNJ

Dow Jones · 2d ago

Please log in to view news